DMK Pharmaceuticals Corporation

Equities

DMKPQ

US00547W3079

Pharmaceuticals

Market Closed - OTC Markets 03:42:29 2024-03-01 pm EST 5-day change 1st Jan Change
0.08 USD -9.34% Intraday chart for DMK Pharmaceuticals Corporation +122.22% -88.58%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DMK Pharmaceuticals Corporation(NasdaqCM:DMK) dropped from S&P TMI Index CI
Motion for Joint Administration Approved for DMK Pharmaceuticals Corporation CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) dropped from NASDAQ Composite Index CI
Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation CI
DMK Pharmaceuticals Corporation Filed for Bankruptcy CI
DMK Pharmaceuticals Corporation Announces Board Appointments CI
Maxim Starts DMK Pharmaceuticals With Buy Rating, $1.50 Price Target MT
DMK Pharmaceuticals Corporation Regains Full Rights from US WorldMeds for SYMJEPI CI
DMK Pharmaceuticals Corporation(OTCPK:DMKP.Q) added to NASDAQ Composite Index CI
Adamis Pharmaceuticals Corporation(NasdaqCM:ADMP) dropped from NASDAQ Composite Index CI
Earnings Flash (DMK) DMK PHARMACEUTICALS CORPORATION Reports Q3 Revenue $9,062 MT
DMK Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
DMK Pharmaceuticals Corporation Announces CFO Changes CI
DMK Pharmaceuticals Corporation Announces Executive Changes CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals CI
Jerald Hammann Submits Shareholder Proposals to DMK Pharmaceuticals CI
Adamis Pharmaceuticals Changes Name to DMK Pharmaceuticals MT
Adamis Pharmaceuticals Corporation has Changed its Name to DMK Pharmaceuticals Corporation CI
Earnings Flash (ADMP) ADAMIS PHARMACEUTICALS CORPORATION Posts Q2 Revenue $6,945 MT
Adamis Pharmaceuticals Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Sector Update: Health Care Stocks Slipping Late Friday MT
Sector Update: Health Care MT
Adamis Pharmaceuticals Closes $8 Million Units Offering; Shares Fall MT
Top Premarket Gainers MT
Sector Update: Health Care Stocks Ease Late Wednesday MT
Chart DMK Pharmaceuticals Corporation
More charts
DMK Pharmaceuticals Corporation, formerly Adamis Pharmaceuticals Corporation, is a commercial stage neuro-biotech company. The Company is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
  1. Stock
  2. Equities
  3. Stock DMK Pharmaceuticals Corporation - OTC Markets
  4. News DMK Pharmaceuticals Corporation
  5. Maxim Starts DMK Pharmaceuticals With Buy Rating, $1.50 Price Target
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW